Publications by authors named "Gavin Callaghan"

Article Synopsis
  • Primary sclerosing cholangitis (PSC) is a chronic liver disease, and liver transplantation is the only established treatment; this study evaluates the effects of biologics in PSC patients with inflammatory bowel disease (IBD).
  • A systematic review and meta-analysis of six studies (including 411 patients) found no significant change in alkaline phosphatase levels with biologics, but a small increase in total bilirubin and a notable response in ulcerative colitis symptoms.
  • The study concludes that while biologics can help treat colitis associated with PSC, they do not improve liver biochemical markers and vedolizumab may worsen liver enzyme levels, indicating a need for more research.
View Article and Find Full Text PDF

Background: Catheter-related bloodstream infections (CRBSIs) in patients receiving home parenteral nutrition (HPN) for chronic intestinal failure (CIF) are associated with significant morbidity and financial costs. Taurolidine is associated with a reduction in bloodstream infections, with limited information on the cost-effectiveness as the primary prevention. This study aimed to determine the cost-effectiveness of using taurolidine-citrate for the primary prevention of CRBSIs within a quaternary hospital.

View Article and Find Full Text PDF

In patients with primary sclerosing cholangitis (PSC), antimicrobial therapy with oral vancomycin (OV) is increasingly used to prevent progression of the liver disease and control concomitant ulcerative colitis (UC); however, there are concerns regarding the risk of development of vancomycin-resistant enterococci (VRE). Thus, we aimed to determine the incidence of VRE in PSC-UC patients. We conducted a retrospective study of PSC-UC patients, treated with OV at the Department of Gastroenterology at the Princess Alexandra Hospital.

View Article and Find Full Text PDF

Background And Aims: Antimicrobial therapy improves symptoms in patients with irritable bowel syndrome (IBS), but the efficacy in functional dyspepsia (FD) is largely unknown. While FD and IBS frequently overlap, it is unknown if concomitant IBS in FD alters the response to antimicrobial therapy in FD. Thus, we aimed to assess and compare the effect of antimicrobial therapy on visceral sensory function and symptom improvement in FD patients with and without IBS.

View Article and Find Full Text PDF